Tuxera
27.2.2024 14:04:00 CET | ACCESS Newswire | Press release
The new agreement allows Tuxera to provide customers SMB technology along with an SMB license from Microsoft in a single solution.
HELSINKI, FINLAND / ACCESSWIRE / February 27, 2024 / Tuxera is expanding its collaboration with Microsoft through a new Server Message Block (SMB) partner agreement. The agreement enables innovative business solutions for customers by allowing Tuxera to provide SMB technology and an SMB patent license from Microsoft in one competitively priced solution.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Red TUXERA logo with Fusion File Share by Tuxera logo on a purple nebula space background.
"Currently we see huge demand for unstructured data from different industries and use cases. We see media and entertainment with a growing need of collaboration with very large video contents, healthcare with requirements on large imaging contents for AI scenarios, and many more require fast file transfers that we provide," says Antti Alila, VP Enterprise Business at Tuxera. "Having compliant software solutions including patents, business critical support, and future innovation is highly welcome in this market."
"Building on top of our strong collaboration with Tuxera, this agreement enables customers to focus on file sharing scenarios and innovations using compliant, quality solutions for SMB file transfer," says Rob Kowal, Director of IP Licensing at Microsoft.
SMB is the native Microsoft protocol used to share files over a local area network, virtual private network, and cloud-based solutions. It is widely adopted worldwide, thanks in part to Window's global reach. According to Statista, about 70% of the global desktop operating systems use Windows.
SMB is common in mixed environments due to its interoperability. It allows seamless file transfer between Windows and non-Windows-based operating systems, as well as between many different types of devices.
This new agreement lowers any perceived hassle or barriers for licensing SMB technology. It also adds significant value for customers who use Fusion File Share by Tuxera, which provides the fastest and most reliable access to shared file resources and enterprise-grade features unique among SMB implementations using Linux.
Tuxera is the only company to offer a fully licensed, high-availability, cloud-scale SMB solution for enterprise storage requirements, as well as SMB for embedded devices.
Tuxera has been collaborating with Microsoft from 2009 onward and is also a designated licensing aggregator for exFAT technology since 2019. This new agreement builds on earlier cooperation with Microsoft to develop and release a product based on Microsoft's SMB technology, Fusion File Share by Tuxera.
More information about Microsoft's licensing program is available at their Tech Licensing programs page. To learn more about combining SMB technology and licensing in one solution, please contact sales@tuxera.com.
About Tuxera
Tuxera is the leading provider of quality-assured data storage management software and networking technologies. Our software is at the core of products used all around the world, including phones, cars, TV sets, cameras, drones, external storage, routers, spacecraft, IoT devices, and public cloud storage platforms. Tuxera's customers include car makers, device manufacturers, industrial equipment manufacturers, data-driven enterprises, and much more. They rely on our software to protect data integrity and accessibility, improve storage performance, transfer data rapidly and securely, and extend flash memory lifetime in their products and for their projects. We are also members of JEDEC, AGL, SD Association, The Linux Foundation, and other industry associations. Founded in 2008, Tuxera's headquarters are located in Finland, with regional offices in China, Germany, Hungary, South Korea, Japan, Taiwan, and the U.S.
Contact Information
Sagan Rossi
Head of Marketing, Tuxera
press@tuxera.com
SOURCE: Tuxera
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
RE Royalties Announces Second Tranche Investment of $800,000 in Solaris Energy's U.S. Distributed Generation Solar Portfolio9.2.2026 23:00:00 CET | Press release
All amounts in US dollars unless otherwise stated. VANCOUVER, BC / ACCESS Newswire / February 9, 2026 / RE Royalties Ltd. (TSX.V:RE)(OTCQX:RROYF)(FSE:Y2V) ("RE Royalties" or the "Company") is pleased to announce a further USD $800,000 investment toward the purchase of royalties on two portfolios of distributed generation ("DG") solar projects located throughout the United States being developed by Solaris Energy Inc. ("Solaris"). The Royalty Purchase for Portfolio 1 totals USD $4.8 million, of which USD $3 million was funded at closing, as announced on January 7, 2026. The Company expects to fund the remaining USD $1 million by Q2 2026, subject to the satisfaction of applicable conditions. The Royalty Purchase for Portfolio 2 is subject to the completion of due diligence to the satisfaction of the Company, other customary closing conditions, and is expected to occur later in the year, bringing the total portfolio level royalty investment to USD $9 million. The Royalty Rate will be adju
UK-Based Vesalic Limited Emerges from Stealth with Landmark Discovery of Potential Non-CNS Driver of Motor Neuron Diseases, including ALS, and Breakthrough Therapeutic and Diagnostic Opportunities9.2.2026 06:00:00 CET | Press release
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo in ALS patients, which is carried to the CNS, where it binds to and damages neurons Vesalic is pioneering a novel therapeutic to intercept and neutralise these toxins, potentially slowing or halting progression of monogenic and sporadic forms of ALS In addition, Vesalic has discovered a disease-specific alteration of the lipid composition in the membranes of exosomes circulating in the blood, and has developed a highly accurate biomarker-based technology to detect both monogenic and sporadic ALS Based on its novel biomarker discoveries, Vesalic is also applying its biomarker technology for other neurodegenerative diseases, including Alzheimer's and Parkinson's LONDON, UK / ACCESS Newswire / February 9, 2026 / Vesalic Limited, an early-stage neurodegenerative disease-focused biotech company, today emerged from stealth with the landmark discovery of a systemic process - largely
Innodata to Report Fourth Quarter and Fiscal Year 2025 Results5.2.2026 14:30:00 CET | Press release
NEW YORK, NY / ACCESS Newswire / February 5, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it will report Fourth Quarter and Fiscal Year 2025 results after the market closes on Thursday, February 26, 2026. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com. Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are: (+1) 800 549 8228 North America (+44) 800 279 7040 United Kingdom (+1) 289 819 1520 International Participant Access Code 27117 # Replay dial-In (+1) 888 660 6264 North America (+1) 289 819 1325 International: Replay Passcode 27117 # Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only mode. Call-in replay will be av
Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 20265.2.2026 12:00:00 CET | Press release
Datavault AI signed $49M of Tokenization and Technology Licensing agreements in Q4'25 that impact FY2025 and FY2026 Revenue. Revenue: Datavault AI expects at least $30 million in revenue for FY2025, compared to $2.7 million in FY2024. This represents an increase of more than 1,000% growth in our revenue over 2024. The Company continues to expand to drive substantial near- and long-term accretion to our cash flows and earnings with a revenue target for 2026 of at least $200 million. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 5, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, today issued a letter from Nathaniel Bradley, its Chief Executive Officer, to its stockholders highlighting the Company's accomplishments in 2025 and its outlook for 2026. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Dear Datavault AI Stockholders, I would like t
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
